Alternative device for increased specificity of bronchoscopic lung cancer detection

Research published in the September 2009 issue of the Journal of Thoracic Oncology has found that narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection and can serve as an alternative detection device.

Past research has shown detection of non-small cell lung cancer (NSCLC) while still localized to the surface of the lung can improve cure rates. Bronchoscopic technologies that utilize white light (WLB), auto-fluorescence imaging (AFI) and narrow-band imaging (NBI) have been developed to enhance the ability for physicians to diagnoses NSCLC at a pre-invasive stage. NBI is the newest of these technologies.

To confirm the efficiency of these new technologies, Felix J.F. Herth, M.D. of the Department of Pneumology and Critical Care Medicine at the University of Heidelberg in Germany and his team of researchers conducted a 10-month review of patients in need of airway screening and surveillance. Patients were randomized into groups receiving WFB, AFI or NBI bronchoscopies and any observed abnormal airway mucosa was biopsied.

Out of 57 patients, 30 percent were diagnosed with intraepithelial neoplasia. Researchers found that those observed with NBI and AFI bronchoscopies experienced significantly superior sensitivities compared to WLB alone. NBI also proved to provide high levels of specificity compared to AFI.

"This research shows that when diagnosing early stage lung cancer, using NBI may be a better option than AFI because it increases specificity without compromising sensitivity," said Dr. Herth. "Continued research on these detection methods is necessary to further understand the best, most accurate ways to increase early diagnosis in lung cancer."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered tool predicts gene activity in cancer cells from biopsy images